Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 9/2012

01-09-2012 | Symposium-in-writing paper

Involvement of eosinophils in the anti-tumor response

Authors: Solène Gatault, Fanny Legrand, Marie Delbeke, Sylvie Loiseau, Monique Capron

Published in: Cancer Immunology, Immunotherapy | Issue 9/2012

Login to get access

Abstract

Eosinophils have long been associated with allergy and parasitic infections. Today, they are considered as multifunctional leukocytes, which participate both in innate and adaptive immune response though the expression of various receptors and mediators. Although the tumor-associated eosinophilia is observed for a long time in many hematological and solid malignancies, with a generally good prognosis value, there is a lack of knowledge on the different mechanisms involved in this phenomenon. Moreover, the recent discovery in human eosinophils of different receptors and mediators, shared with lymphocytes and involved in anti-tumor defense, suggests that eosinophils can play a role in anti-tumoral immunity. We review in the present paper the current knowledge on epidemiology, recruitment, and mechanisms involved in the response of eosinophils toward tumors.
Literature
1.
Munitz A, Levi-Schaffer F (2004) Eosinophils: ‘new’ roles for ‘old’ cells. Allergy 59(3):268–275PubMedCrossRef
2.
Lowe D, Jorizzo J, Hutt MS (1981) Tumour-associated eosinophilia: a review. J Clin Pathol 34(12):1343–1348PubMedCrossRef
3.
Kita H (2011) Eosinophils: multifaceted biological properties and roles in health and disease. Immunol Rev 242(1):161–177PubMedCrossRef
4.
Driss V, Legrand F, Hermann E, Loiseau S, Guerardel Y, Kremer L, Adam E, Woerly G, Dombrowicz D, Capron M (2009) TLR2-dependent eosinophil interactions with mycobacteria: role of alpha-defensins. Blood 113(14):3235–3244PubMedCrossRef
5.
Legrand F, Driss V, Delbeke M, Loiseau S, Hermann E, Dombrowicz D, Capron M (2010) Human eosinophils exert TNF-alpha and granzyme A-mediated tumoricidal activity toward colon carcinoma cells. J Immunol 185(12):7443–7451PubMedCrossRef
6.
Legrand F, Driss V, Woerly G, Loiseau S, Hermann E, Fournie JJ, Heliot L, Mattot V, Soncin F, Gougeon ML, Dombrowicz D, Capron M (2009) A functional gammadeltaTCR/CD3 complex distinct from gammadeltaT cells is expressed by human eosinophils. PLoS ONE 4(6):e5926PubMedCrossRef
7.
Munitz A, Bachelet I, Fraenkel S, Katz G, Mandelboim O, Simon HU, Moretta L, Colonna M, Levi-Schaffer F (2005) 2B4 (CD244) is expressed and functional on human eosinophils. J Immunol 174(1):110–118PubMed
8.
9.
Gleich GJ (2000) Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 105(4):651–663PubMedCrossRef
10.
Hogan SP, Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy P, Kay AB, Rothenberg ME (2008) Eosinophils: biological properties and role in health and disease. Clin Exp Allergy 38(5):709–750PubMedCrossRef
11.
Abu-Ghazaleh RI, Gleich GJ, Prendergast FG (1992) Interaction of eosinophil granule major basic protein with synthetic lipid bilayers: a mechanism for toxicity. J Membr Biol 128(2):153–164PubMed
12.
Lucey DR, Nicholson-Weller A, Weller PF (1989) Mature human eosinophils have the capacity to express HLA-DR. Proc Natl Acad Sci USA 86(4):1348–1351PubMedCrossRef
13.
Spencer LA, Weller PF (2010) Eosinophils and Th2 immunity: contemporary insights. Immunol Cell Biol 88(3):250–256PubMedCrossRef
14.
Yang D, Chen Q, Su SB, Zhang P, Kurosaka K, Caspi RR, Michalek SM, Rosenberg HF, Zhang N, Oppenheim JJ (2008) Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2-MyD88 signal pathway in dendritic cells and enhances Th2 immune responses. J Exp Med 205(1):79–90PubMedCrossRef
15.
Lee JJ, Jacobsen EA, McGarry MP, Schleimer RP, Lee NA (2010) Eosinophils in health and disease: the LIAR hypothesis. Clin Exp Allergy 40(4):563–575PubMedCrossRef
16.
Pretlow TP, Keith EF, Cryar AK, Bartolucci AA, Pitts AM, Pretlow TG II, Kimball PM, Boohaker EA (1983) Eosinophil infiltration of human colonic carcinomas as a prognostic indicator. Cancer Res 43(6):2997–3000PubMed
17.
Fernandez-Acenero MJ, Galindo-Gallego M, Sanz J, Aljama A (2000) Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer 88(7):1544–1548PubMedCrossRef
18.
Dorta RG, Landman G, Kowalski LP, Lauris JR, Latorre MR, Oliveira DT (2002) Tumour-associated tissue eosinophilia as a prognostic factor in oral squamous cell carcinomas. Histopathology 41(2):152–157PubMedCrossRef
19.
Ishibashi S, Ohashi Y, Suzuki T, Miyazaki S, Moriya T, Satomi S, Sasano H (2006) Tumor-associated tissue eosinophilia in human esophageal squamous cell carcinoma. Anticancer Res 26(2B):1419–1424PubMed
20.
Fujii M, Yamashita T, Ishiguro R, Tashiro M, Kameyama K (2002) Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma. Auris Nasus Larynx 29(2):175–181PubMedCrossRef
21.
Ono Y, Ozawa M, Tamura Y, Suzuki T, Suzuki K, Kurokawa K, Fukabori Y, Yamanaka H (2002) Tumor-associated tissue eosinophilia of penile cancer. Int J Urol 9(2):82–87PubMedCrossRef
22.
Costello R, O’Callaghan T, Sebahoun G (2005) Eosinophils and antitumour response. Rev Med Interne 26(6):479–484PubMedCrossRef
23.
Luna-More S, Florez P, Ayala A, Diaz F, Santos A (1997) Neutral and acid mucins and eosinophil and argyrophil crystalloids in carcinoma and atypical adenomatous hyperplasia of the prostate. Pathol Res Pract 193(4):291–298PubMedCrossRef
24.
von Wasielewski R, Seth S, Franklin J, Fischer R, Hubner K, Hansmann ML, Diehl V, Georgii A (2000) Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin’s disease, allowing for known prognostic factors. Blood 95(4):1207–1213
25.
Pinto A, Aldinucci D, Gloghini A, Zagonel V, Degan M, Improta S, Juzbasic S, Todesco M, Perin V, Gattei V, Herrmann F, Gruss HJ, Carbone A (1996) Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin’s disease cell line. Blood 88(9):3299–3305PubMed
26.
Geisinger KR, Steffee CH, McGee RS, Woodruff RD, Buss DH (1998) The cytomorphologic features of sclerosing mucoepidermoid carcinoma of the thyroid gland with eosinophilia. Am J Clin Pathol 109(3):294–301PubMed
27.
Fridlender ZG, Simon HU, Shalit M (2003) Metastatic carcinoma presenting with concomitant eosinophilia and thromboembolism. Am J Med Sci 326(2):98–101PubMedCrossRef
28.
Dibbert B, Daigle I, Braun D, Schranz C, Weber M, Blaser K, Zangemeister-Wittke U, Akbar AN, Simon HU (1998) Role for Bcl-xL in delayed eosinophil apoptosis mediated by granulocyte-macrophage colony-stimulating factor and interleukin-5. Blood 92(3):778–783PubMed
29.
Teruya-Feldstein J, Jaffe ES, Burd PR, Kingma DW, Setsuda JE, Tosato G (1999) Differential chemokine expression in tissues involved by Hodgkin’s disease: direct correlation of eotaxin expression and tissue eosinophilia. Blood 93(8):2463–2470PubMed
30.
Lorena SC, Oliveira DT, Dorta RG, Landman G, Kowalski LP (2003) Eotaxin expression in oral squamous cell carcinomas with and without tumour associated tissue eosinophilia. Oral Dis 9(6):279–283PubMedCrossRef
31.
Thielen C, Radermacher V, Trimeche M, Roufosse F, Goldman M, Boniver J, de Leval L (2008) TARC and IL-5 expression correlates with tissue eosinophilia in peripheral T-cell lymphomas. Leuk Res 32(9):1431–1438PubMedCrossRef
32.
Cormier SA, Taranova AG, Bedient C, Nguyen T, Protheroe C, Pero R, Dimina D, Ochkur SI, O’Neill K, Colbert D, Lombari TR, Constant S, McGarry MP, Lee JJ, Lee NA (2006) Pivotal advance: eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J Leukoc Biol 79(6):1131–1139PubMedCrossRef
33.
Stenfeldt AL, Wenneras C (2004) Danger signals derived from stressed and necrotic epithelial cells activate human eosinophils. Immunology 112(4):605–614PubMedCrossRef
34.
Lotfi R, Lee JJ, Lotze MT (2007) Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J Immunother 30(1):16–28PubMedCrossRef
35.
Ito N, DeMarco RA, Mailliard RB, Han J, Rabinowich H, Kalinski P, Stolz DB, Zeh HJ III, Lotze MT (2007) Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol 81(1):75–83PubMedCrossRef
36.
Lotfi R, Herzog GI, DeMarco RA, Beer-Stolz D, Lee JJ, Rubartelli A, Schrezenmeier H, Lotze MT (2009) Eosinophils oxidize damage-associated molecular pattern molecules derived from stressed cells. J Immunol 183(8):5023–5031PubMedCrossRef
37.
Sun P, Ben Q, Tu S, Dong W, Qi X, Wu Y (2011) Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci 56(12):3596–3601PubMedCrossRef
38.
Ikutani M, Yanagibashi T, Ogasawara M, Tsuneyama K, Yamamoto S, Hattori Y, Kouro T, Itakura A, Nagai Y, Takaki S, Takatsu K (2011) Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity. J Immunol 188(2):703–713PubMedCrossRef
39.
Caruso RA, Parisi A, Quattrocchi E, Scardigno M, Branca G, Parisi C, Luciano R, Paparo D, Fedele F (2011) Ultrastructural descriptions of heterotypic aggregation between eosinophils and tumor cells in human gastric carcinomas. Ultrastruct Pathol 35(4):145–149PubMedCrossRef
40.
Huland E, Huland H (1992) Tumor-associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells. J Cancer Res Clin Oncol 118(6):463–467PubMedCrossRef
41.
Simon HU, Plotz S, Simon D, Seitzer U, Braathen LR, Menz G, Straumann A, Dummer R, Levi-Schaffer F (2003) Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells’ syndrome. Eur J Immunol 33(4):834–839PubMedCrossRef
42.
Sosman JA, Bartemes K, Offord KP, Kita H, Fisher SG, Kefer C, Ellis TA, Fisher RI, Higgins TJ, Gleich GJ (1995) Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration. Clin Cancer Res 1(8):805–812PubMed
43.
Tepper RI, Coffman RL, Leder P (1992) An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 257(5069):548–551PubMedCrossRef
44.
Rivoltini L, Viggiano V, Spinazze S, Santoro A, Colombo MP, Takatsu K, Parmiani G (1993) In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5. Int J Cancer 54(1):8–15PubMedCrossRef
45.
Benatar T, Cao MY, Lee Y, Lightfoot J, Feng N, Gu X, Lee V, Jin H, Wang M, Wright JA, Young AH (2010) IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo. Cancer Immunol Immunother 59(6):805–817PubMedCrossRef
46.
Mattes J, Hulett M, Xie W, Hogan S, Rothenberg ME, Foster P, Parish C (2003) Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med 197(3):387–393PubMedCrossRef
47.
Simson L, Ellyard JI, Dent LA, Matthaei KI, Rothenberg ME, Foster PS, Smyth MJ, Parish CR (2007) Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol 178(7):4222–4229PubMed
48.
Turner MC, Chen Y, Krewski D, Ghadirian P (2006) An overview of the association between allergy and cancer. Int J Cancer 118(12):3124–3132PubMedCrossRef
49.
Wang H, Diepgen TL (2005) Is atopy a protective or a risk factor for cancer? A review of epidemiological studies. Allergy 60(9):1098–1111PubMedCrossRef
50.
Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M, Penichet ML, Rodriguez JA, Siccardi AG, Vangelista L, Riemer AB, Gould H (2008) AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy 63(10):1255–1266PubMedCrossRef
51.
Tomassini M, Tsicopoulos A, Tai PC, Gruart V, Tonnel AB, Prin L, Capron A, Capron M (1991) Release of granule proteins by eosinophils from allergic and nonallergic patients with eosinophilia on immunoglobulin-dependent activation. J Allergy Clin Immunol 88(3 Pt 1):365–375PubMedCrossRef
52.
Gounni AS, Lamkhioued B, Ochiai K, Tanaka Y, Delaporte E, Capron A, Kinet JP, Capron M (1994) High-affinity IgE receptor on eosinophils is involved in defence against parasites. Nature 367(6459):183–186PubMedCrossRef
53.
Jonsson UB, Bystrom J, Stalenheim G, Venge P (2002) Polymorphism of the eosinophil cationic protein-gene is related to the expression of allergic symptoms. Clin Exp Allergy 32(7):1092–1095PubMedCrossRef
54.
Molin D (2004) Bystander cells and prognosis in Hodgkin lymphoma. Review based on a doctoral thesis. Ups J Med Sci 109(3):179–228PubMedCrossRef
Metadata
Title
Involvement of eosinophils in the anti-tumor response
Authors
Solène Gatault
Fanny Legrand
Marie Delbeke
Sylvie Loiseau
Monique Capron
Publication date
01-09-2012
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 9/2012
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-012-1288-3

Other articles of this Issue 9/2012

Cancer Immunology, Immunotherapy 9/2012 Go to the issue

Original Article

Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma

Symposium-in-writing paper

How to connect an IgE-driven response with CTL activity?

Symposium-in-writing paper

Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization

Symposium-in-writing paper

Activation-induced cytidine deaminase (AID) linking immunity, chronic inflammation, and cancer

Symposium-in-writing paper

Animal models for IgE-meditated cancer immunotherapy

Symposium-in-writing paper

Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits